IGF-1 LR3 Peptide UK: Long R3 IGF-I Evidence in the Peptides UK Market
IGF-1 LR3 Peptide UK: Long R3 IGF-I Evidence in the Peptides UK Market
IGF-1 LR3, usually written Long R3 IGF-I in scientific literature, is an engineered 83-amino-acid analogue of human insulin-like growth factor 1. It combines the complete mature IGF-1 sequence with a 13-residue N-terminal extension and replacement of glutamic acid by arginine at position three of the IGF-1 domain. These changes markedly reduce binding to insulin-like growth factor-binding proteins while retaining activity at the type 1 IGF receptor. The molecule was developed principally as a potent mammalian-cell-culture supplement rather than as an authorised human medicine.
Direct Answer
IGF-1 LR3 is a recombinant analogue of human insulin-like growth factor 1 containing 83 amino-acid residues. It has a 13-amino-acid extension at its N-terminus and an arginine in place of the glutamic acid normally found at position three of mature human IGF-1.
The modifications weaken its interaction with IGF-binding proteins. This can leave a larger proportion of the molecule available to activate IGF-1 receptors in cell-culture systems and selected animal models.
The name “Long” describes the additional N-terminal sequence. It should not be interpreted automatically as meaning that the molecule has a longer circulating half-life than native IGF-1. Animal research has reported that reduced binding-protein affinity can increase clearance while producing stronger tissue or glucose-lowering effects.
Long R3 IGF-I was engineered primarily to support mammalian cells during biopharmaceutical manufacturing. It is widely used as a research growth factor in serum-free cell-culture media.
No published clinical programme establishing the safety or effectiveness of standalone IGF-1 LR3 in humans was identified in the sources reviewed. Bodybuilding, local-muscle-growth, injury-repair, fat-loss, anti-ageing and performance claims rely on laboratory, animal or anecdotal information rather than controlled human trials.
IGF-1 LR3 Peptide Key Points
The main scientific and regulatory facts for readers researching IGF-1 LR3 within the Peptides UK market.
What Is IGF-1 LR3 Peptide?
Long R3 IGF-I is a laboratory-engineered growth-factor analogue rather than a naturally occurring human hormone.
Native mature human IGF-1 is a single-chain protein containing 70 amino-acid residues and three intramolecular disulphide bridges.
IGF-1 LR3 contains all 70 residues of the mature IGF-1 domain, subject to one substitution, together with a 13-residue extension placed before the natural N-terminus.
The native glutamic acid at position three of human IGF-1 is replaced with arginine. The notation R3 refers to this arginine substitution.
The resulting molecule is commonly described as Long Arg3 IGF-I, Long R3 IGF-I, LR3 IGF-I or IGF-1 LR3.
At approximately 9.1 kilodaltons, it is larger and structurally more complex than many short peptides sold through research catalogues. It may also be described more accurately as a small recombinant protein.
IGF-1 LR3 Names and Terminology
Similar-looking names can refer to structurally different growth factors.
| Name | Basic Meaning | Important Distinction |
|---|---|---|
| Long R3 IGF-I | Scientific name used frequently in research papers | Contains both the N-terminal extension and Glu3-to-Arg substitution |
| IGF-1 LR3 | Commercially common rearrangement of the name | Usually intended to refer to Long R3 IGF-I |
| R3 IGF-I | Seventy-residue IGF-1 with only the Glu3-to-Arg substitution | Does not contain the 13-residue extension |
| Long IGF-I | IGF-1 with the extension but without the R3 substitution | Different binding and potency profile |
| Native IGF-1 | Natural 70-residue mature human growth factor | Binds strongly to IGF-binding proteins |
| Mecasermin | Recombinant human IGF-1 medicine | Authorised for a restricted medical indication and not an LR3 analogue |
| Des(1–3) IGF-I | IGF-1 lacking its first three residues | Another low-IGFBP-affinity analogue with a different sequence |
A label stating only “IGF-1” is insufficient
An analytical document should distinguish native IGF-1, mecasermin, R3 IGF-I, Long IGF-I, Long R3 IGF-I and Des(1–3) IGF-I. They are not interchangeable substances.
IGF-1 LR3 Research in the Peptides UK Market
Commercial promotion commonly repurposes cell-culture and animal findings as personal-use claims.
IGF-1 LR3 appears in Peptides UK catalogues as a recombinant research protein, lyophilised vial or component within products marketed around muscle growth and recovery.
Typical promotional claims include increased muscle size, localised growth, improved protein synthesis, faster injury repair, enhanced nutrient uptake, fat reduction, increased strength and improved workout recovery.
These descriptions often omit that Long R3 IGF-I was engineered principally for use in mammalian cell culture, where its reduced binding-protein affinity makes it an efficient growth and survival supplement.
Research showing proliferation of cultured cells is not clinical evidence that the molecule builds safe, functional or proportionate skeletal muscle in a person.
Animal experiments demonstrate that the molecule can affect glucose, organ growth, endogenous hormone concentrations and multiple tissues. These are reasons for caution rather than proof of controlled muscle selectivity.
“Research grade” does not mean suitable for personal research
In legitimate scientific use, research-grade Long R3 IGF-I is handled within controlled laboratories and added to validated cell-culture systems. The term does not establish suitability for administration to a person.
What Does Native IGF-1 Do?
Understanding normal IGF-1 biology helps explain why bypassing its regulatory system may carry broad effects.
IGF-1 is produced in the liver and many other tissues. Growth hormone is an important regulator of hepatic IGF-1 production, although nutrition, insulin, age, sex hormones and local tissue signals also influence the system.
IGF-1 supports normal childhood growth and contributes to cell survival, differentiation, protein metabolism and tissue maintenance.
Most circulating IGF-1 is not freely available to receptors. It is carried by a family of IGF-binding proteins, particularly IGFBP-3 within a larger complex containing the acid-labile subunit.
Binding proteins extend the circulating persistence of native IGF-1, influence its delivery to tissues and limit immediate receptor exposure.
The body therefore regulates IGF-1 through production, binding proteins, receptor density, receptor signalling and feedback effects on growth hormone.
IGF-1 is not simply a muscle-growth switch
IGF-1 receptors are found in numerous tissues. Signalling can influence skeletal muscle, bone, cartilage, nerves, the cardiovascular system, internal organs and cells capable of abnormal proliferation.
IGF-1 LR3 Molecular and Scientific Profile
Correct identification requires confirmation of its extension, substitution, complete sequence and three native disulphide bonds.
Long R3 IGF-I
An 83-residue, normally non-glycosylated recombinant polypeptide containing a modified human IGF-1 domain.
Its approximate molecular mass is 9.1 kilodaltons.
IGF-1 Receptor Agonist
The analogue retains activity at the type 1 IGF receptor while interacting much less strongly with several IGF-binding proteins.
Biological potency therefore depends heavily on the binding proteins present in the experimental system.
| Preferred scientific name | Long R3 insulin-like growth factor I |
|---|---|
| Common commercial name | IGF-1 LR3 |
| Length | 83 amino-acid residues |
| Native IGF-1 domain | 70 residues |
| N-terminal extension | 13 residues |
| Primary substitution | Glu3 to Arg within the IGF-1 domain |
| Approximate molecular mass | Approximately 9.1 kDa |
| Disulphide bonds | Three intramolecular bonds within the IGF-1 domain |
| Primary receptor | Type 1 IGF receptor |
| IGF-binding-protein affinity | Substantially lower than native IGF-1 |
| Established human indication | None identified |
IGF-1 LR3 Amino-Acid Sequence
The molecule contains the extension followed by the modified mature human IGF-1 sequence.
The commonly described single-letter sequence is:
The first 13 residues, MFPAMPLSSLFVN, form the non-native N-terminal extension.
The following modified IGF-1 domain begins GPRT rather than the native GPET sequence because arginine replaces glutamic acid at position three.
Using native IGF-1 numbering, the correctly folded molecule contains disulphide bonds between Cys6 and Cys48, Cys18 and Cys61, and Cys47 and Cys52.
When numbered across the complete 83-residue LR3 sequence, these correspond to bonds between Cys19 and Cys61, Cys31 and Cys74, and Cys60 and Cys65.
The correct sequence does not prove the correct fold
IGF-1 can form alternative disulphide isomers. A product may contain all expected amino acids and still have incorrect cysteine pairing and substantially altered receptor activity.
What Do the “Long” and “R3” Modifications Change?
Both modifications were selected to alter production, folding and interaction with IGF-binding proteins.
The Thirteen-Residue Extension
The extension was derived from an N-terminal region used in recombinant fusion-protein production.
It helped improve production and folding of biologically active IGF analogues in bacterial expression systems.
The extension also contributes to reduced interaction with IGF-binding proteins.
The Glu3-to-Arg Substitution
Native human IGF-1 contains glutamic acid at position three. Long R3 IGF-I contains positively charged arginine at this position.
Research comparing several variants showed that the substitution strongly reduces IGFBP binding while maintaining meaningful IGF-1 receptor activity.
Combined Effect
Long R3 IGF-I is particularly potent in cell systems that release inhibitory IGF-binding proteins into the culture medium.
In cells that do not produce detectable binding proteins, LR3 can be no more potent or even less potent than native IGF-1.
IGF-1 LR3 and IGF-Binding Proteins
Reduced binding-protein affinity is the defining biological feature of the molecule.
Six classical high-affinity IGF-binding proteins help regulate the distribution and activity of IGF-1 and IGF-2.
In circulation, IGFBP-3 is the predominant carrier and commonly participates in a ternary complex with IGF-1 and the acid-labile subunit.
Binding can protect native IGF-1 from rapid clearance while reducing immediate availability to cell-surface receptors.
Long R3 IGF-I has dramatically reduced affinity for IGFBPs. One embryo-culture study reported binding affinity at least three orders of magnitude lower than native IGF-1 under the tested conditions.
This can increase free receptor-accessible analogue in cell culture. It can also remove an important part of normal biological buffering.
Reduced binding does not mean that LR3 is incapable of interacting indirectly with the IGFBP system. Animal studies reported changes in endogenous IGF-1, IGF-2 and binding-protein concentrations following exposure.
Less binding is not automatically safer or better
Binding proteins are not merely obstacles. They help control transport, tissue delivery, clearance and receptor exposure. Bypassing them may increase activity but also reduce physiological regulation.
IGF-1 LR3, IGF-1 Receptors and Insulin Receptors
The analogue primarily targets IGF-1 receptors but can influence a connected receptor network.
Type 1 IGF Receptor
The IGF-1 receptor is a receptor tyrosine kinase structurally related to the insulin receptor.
Long R3 IGF-I retains substantial IGF-1 receptor affinity, although certain experiments report slightly lower receptor affinity than native IGF-1.
Insulin Receptor
IGF-1 can interact more weakly with insulin receptors, particularly at higher concentrations.
Cell-culture studies also describe activation of insulin receptors and hybrid receptors containing one IGF-1-receptor half and one insulin-receptor half.
Hybrid Receptors
IGF-1 and insulin receptor subunits can assemble into hybrid receptors in several tissues.
These hybrids complicate simple claims that LR3 affects only growth and has no insulin-like metabolic action.
Receptor selectivity is not absolute
The strong glucose-lowering effects reported in animals demonstrate that an IGF-1 analogue can produce clinically relevant insulin-like consequences even where its principal target is the IGF-1 receptor.
How Does IGF-1 LR3 Signal Inside Cells?
Receptor activation can stimulate both growth-related and survival-related pathways.
Binding to the IGF-1 receptor activates its intracellular tyrosine-kinase domains.
Receptor substrates then transmit signals into pathways including phosphoinositide 3-kinase, AKT and mechanistic target of rapamycin.
These pathways can influence glucose transport, protein synthesis, metabolism, cell survival and resistance to programmed cell death.
The receptor can also activate RAS, RAF, MEK and ERK signalling, which contributes to cell-cycle progression, proliferation and differentiation.
Protein synthesis is only one possible consequence
The same signalling network involved in muscle-cell biology also operates in internal organs, connective tissue and many tumour cells. It cannot be assumed to act only where a user intends.
Why Was Long R3 IGF-I Developed for Cell Culture?
Its established practical role is as a potent growth and survival supplement in mammalian-cell production systems.
Mammalian cells used to manufacture antibodies and recombinant proteins require nutrients and growth signals.
Serum supplies many of these factors but introduces variability, complex biological components and contamination risks.
Long R3 IGF-I was engineered to support proliferation and survival in serum-free or low-serum culture while reducing the amount of insulin or native IGF-1 required.
Research in Chinese hamster ovary cells and human embryonic kidney cells found that LR3 could support cell growth and survival at substantially lower concentrations than insulin.
The high potency was linked to activation of IGF-1 receptors, insulin receptors or hybrid receptors in the selected cell systems.
These results are valuable for biopharmaceutical manufacturing because cells remain viable and productive within a controlled vessel.
Cell-culture potency is not a human treatment claim
A molecule chosen because it keeps industrial production cells alive and proliferating should not be described automatically as safe for uncontrolled systemic exposure.
Does “Long R3” Mean Long Acting?
The word “Long” describes sequence length rather than a clinically established prolonged human half-life.
The analogue is called Long R3 because it contains the 13-residue extension.
Native IGF-1 persists in circulation partly because IGF-binding proteins protect it from rapid clearance.
LR3 interacts poorly with these proteins. Animal studies therefore found that it could be cleared from circulation faster than native IGF-1.
Despite faster clearance, its reduced sequestration can increase immediate tissue availability and produce potent biological effects.
In pigs and marmoset monkeys, low-binding-protein-affinity IGF variants produced stronger and more prolonged glucose-lowering effects than native IGF-1.
IGF-1 LR3 Animal Research
Animal experiments confirm broad biological activity but do not establish a safe human enhancement treatment.
Organ and Tissue Growth
Continuous LR3 infusion stimulated growth of selected organs and altered circulating IGF-1, IGF-2 and binding-protein concentrations.
Organ growth is not equivalent to selective skeletal-muscle improvement.
Glucose Reduction
Low-IGFBP-affinity variants were two to three times more potent than native IGF-1 at lowering plasma glucose to its lowest point.
The finding highlights a potentially serious metabolic effect.
Anabolic Measurements
LR3 produced growth and body-composition changes at lower molar exposure than native IGF-1 in selected experiments.
The studies involved controlled research animals rather than athletes or patients.
Body Weight Versus Muscle
One rat study reported that LR3 reduced body-weight loss during food restriction but did not preserve skeletal muscle as expected.
This contradicts simplistic claims of guaranteed muscle protection.
Other models have examined intestinal growth, embryonic development, mammary signalling, protein metabolism and cardiac-cell proliferation.
Results differ according to species, age, nutritional state, tissue, exposure pattern and local binding-protein environment.
Animal growth is not necessarily desirable growth
Increased weight or organ size does not establish improved health, strength, athletic performance or long-term safety.
IGF-1 LR3 Muscle and Anabolic Research
Evidence involving cultured myoblasts and animals is routinely overstated as proof of human bodybuilding effects.
Myoblast Proliferation
IGF-1 signalling participates in muscle-cell proliferation, differentiation and survival.
Long R3 IGF-I has been used in cultured myogenic cells because its reduced IGFBP affinity can produce a strong receptor response.
A culture dish does not reproduce human muscle architecture, blood supply, connective tissue, endocrine feedback or whole-body glucose regulation.
Animal Protein Metabolism
Experiments in cattle, pigs and rodents have investigated nitrogen balance, protein synthesis, body composition and lean-tissue preservation.
Results have not shown a uniform selective increase in skeletal muscle. Some studies reported broader growth effects or limited preservation under catabolic conditions.
No Controlled Human Hypertrophy Trial
No randomised human trial was identified showing that standalone IGF-1 LR3 increases muscle mass, strength or sporting performance safely.
No validated exposure-response relationship, clinical monitoring protocol or long-term risk profile exists for this proposed use.
More signalling does not guarantee better-quality muscle
Muscle function depends on neural control, tendon adaptation, blood supply, training, recovery and tissue architecture. Increasing growth-factor signalling cannot be assumed to improve all of these systems proportionately.
Can IGF-1 LR3 Produce Site-Specific Muscle Growth?
No controlled human evidence establishes reliable localised hypertrophy from administration near a selected muscle.
Online discussions sometimes claim that LR3 acts only near the place where it is introduced.
Peptides can enter local blood vessels and lymphatic pathways, after which systemic distribution may occur.
IGF-1 receptors are present throughout the body, and reduced binding-protein affinity may increase unbound distribution rather than confining the molecule.
Local tissue exposure also cannot guarantee selective action on mature muscle fibres. Fibroblasts, blood vessels, nerves, connective tissue and other nearby cells may express relevant receptors.
No published controlled human study was identified comparing targeted muscle growth with systemic exposure or non-target tissue effects.
The injection location is not a biological targeting system
True tissue targeting generally requires validated delivery technology, receptor selectivity and pharmacokinetic evidence. Physical proximity alone does not provide that assurance.
IGF-1 LR3 Injury, Repair and Recovery Claims
Growth-factor biology provides a plausible research hypothesis but not an established injury treatment.
IGF-1 signalling contributes to cell survival, matrix production and regeneration in several experimental tissues.
This has encouraged research involving muscle injury, bone, cartilage, nerves and intestinal tissue.
Healing requires inflammation, removal of damaged material, vascular supply, mechanical loading, collagen organisation and remodelling.
Excessive or poorly timed growth signalling could produce disorganised tissue, fibrosis or growth of cells that should not be stimulated.
No authorised human indication exists for tendon injury, ligament injury, muscle tears, fractures, neuropathy or postoperative recovery.
Evidence involving native IGF-1, local gene expression or animal models cannot be attributed automatically to externally supplied Long R3 IGF-I.
What Human Evidence Exists for IGF-1 LR3?
Direct human clinical evidence for the standalone analogue is absent or extremely limited.
No Authorised Clinical Development Programme Identified
No marketing authorisation for Long R3 IGF-I was identified through the MHRA or EMA sources reviewed.
No completed conventional clinical programme establishing human pharmacokinetics, therapeutic effectiveness, safe exposure ranges or long-term adverse effects was identified.
IGF-Linked Drug Conjugates
Experimental oncology programmes have investigated drug conjugates containing modified IGF-1-like targeting proteins.
These conjugates are chemically different medicines in which a cytotoxic drug is attached to a modified growth factor.
Their human exposure does not establish the safety of unconjugated Long R3 IGF-I or its use for muscle enhancement.
Black-Market and Anti-Doping Evidence
Anti-doping researchers describe Long R3 IGF-I as an unapproved analogue available through black-market bodybuilding channels.
Detection studies focus on identifying misuse and metabolites rather than demonstrating safety or benefit.
Anecdotes are not a substitute for human trials
User reports cannot establish product identity, exposure, causality, adverse-event frequency or what would have happened without the substance.
IGF-1 LR3 Compared With Mecasermin
The presence of an authorised IGF-1 medicine does not validate the LR3 analogue.
| Feature | IGF-1 LR3 | Mecasermin |
|---|---|---|
| Basic identity | Modified 83-residue IGF-1 analogue | Recombinant human IGF-1 |
| Sequence | N-terminal extension plus Glu3-to-Arg substitution | Matches mature human IGF-1 |
| IGFBP affinity | Markedly reduced | Native-like binding |
| Primary established use | Mammalian cell culture | Severe primary IGF-1 deficiency in eligible children and adolescents |
| Human clinical programme | No adequate programme identified | Regulatory clinical and long-term safety monitoring |
| Product quality | Depends on the research manufacturer | Authorised pharmaceutical specification |
| UK status | No marketing authorisation identified | Prescription medicine |
Increlex contains mecasermin and is authorised for the long-term treatment of growth failure associated with confirmed severe primary IGF-1 deficiency.
Its use requires specialist diagnosis, medical monitoring and management of risks including hypoglycaemia.
Product information also includes warnings concerning intracranial hypertension, tonsillar enlargement, scoliosis progression, slipped capital femoral epiphysis, cardiomegaly and benign or malignant neoplasia.
These adverse effects cannot be assigned directly to LR3 without human evidence. They demonstrate, however, that clinically manipulating IGF-1 signalling is not a minor or risk-free intervention.
Mecasermin evidence cannot be transferred to LR3
The molecules differ in sequence, IGFBP interaction, pharmacology and regulatory manufacturing. An authorised indication for mecasermin is not an implied authorisation for IGF-1 LR3.
IGF-1 LR3 Evidence at a Glance
The evidence supports laboratory utility and strong biological activity, not routine human use.
| Research Question | Evidence Type | Current Finding | Main Limitation |
|---|---|---|---|
| Is LR3 a defined IGF-1 analogue? | Recombinant-protein and structural research | Yes | Commercial products still require batch-specific confirmation |
| Does it contain 83 amino acids? | Sequence and protein-characterisation evidence | Yes | Some sellers confuse LR3 with 70-residue R3 IGF-I |
| Does it bind weakly to IGFBPs? | Competition and ligand-binding assays | Yes, substantially more weakly than native IGF-1 | Affinity differs between IGFBPs and assay systems |
| Does it activate IGF-1 receptors? | Cell-based receptor studies | Yes | Receptor activation does not establish human benefit |
| Is it useful in cell culture? | CHO and HEK293 production studies | Yes | Industrial cell culture is not a human treatment model |
| Does “Long” mean a longer human half-life? | Animal pharmacology | Not established | Reduced IGFBP binding can increase clearance |
| Can it lower blood glucose? | Pig and marmoset studies | Potent glucose lowering reported | No safe human exposure profile |
| Can it stimulate tissue growth? | Cell and animal studies | Yes, in selected tissues and models | Growth is not muscle selective or necessarily beneficial |
| Does it increase human muscle mass? | Controlled clinical evidence | Not established | No adequate human hypertrophy trial identified |
| Does it increase human strength? | Controlled clinical evidence | Not established | No trial with validated strength outcomes identified |
| Does it cause localised muscle growth? | Human clinical evidence | Not established | No validated tissue-targeting evidence |
| Does it repair injuries? | Mostly mechanistic and preclinical research | Not established clinically | No authorised injury indication |
| Is long-term human safety known? | Clinical evidence | No | No adequate safety programme identified |
| Is it approved in the UK? | Official product-source review | No marketing authorisation identified | Online availability is not approval |
| Is it prohibited in sport? | WADA 2026 Prohibited List | Yes, as an IGF-1 analogue | Prohibition applies at all times |
Important IGF-1 LR3 Research Limitations
Commercial summaries frequently remove the experimental context needed to understand the findings.
- The molecule was developed principally for mammalian cell culture.
- Many studies investigate cells rather than living organisms.
- Cell lines may express abnormal receptor concentrations.
- Cell-culture media lack normal endocrine feedback.
- Cell-culture potency depends strongly on the presence of IGFBPs.
- Animal species differ in IGF-binding proteins and receptor biology.
- Several animal experiments used continuous infusion.
- Continuous infusion does not model every proposed commercial use.
- Animal organ growth is not evidence of beneficial human growth.
- Animal glucose effects suggest risk rather than treatment benefit.
- No validated human pharmacokinetic profile was identified.
- No established human half-life was identified.
- No controlled human muscle-growth trial was identified.
- No controlled human strength trial was identified.
- No localised-hypertrophy trial was identified.
- No human injury-repair indication was established.
- No long-term cardiovascular safety programme was identified.
- No long-term cancer-safety programme was identified.
- No reproductive or developmental safety programme was identified.
- No paediatric LR3 safety programme was identified.
- No validated interaction studies with insulin or diabetes medicines were identified.
- No reliable adverse-event incidence can be calculated.
- Research-market products may not contain LR3.
- Products may contain native IGF-1 or R3 IGF-I instead.
- Incorrect disulphide folding can reduce or alter activity.
- HPLC alone may not distinguish every folding isomer.
- Bacterial expression can introduce host-cell impurities and endotoxin.
- Storage conditions can cause oxidation, aggregation or degradation.
- Black-market anecdotes lack verified product identity.
IGF-1 LR3 and Hypoglycaemia
Potent glucose lowering is one of the clearest safety concerns supported by animal evidence.
IGF-1 signalling can increase glucose uptake and suppress hepatic glucose production.
Its receptor network overlaps with insulin signalling, and some cells contain IGF-1 and insulin hybrid receptors.
In pigs and marmoset monkeys, IGF-1 variants with poor binding-protein affinity produced glucose-lowering effects two to three times more potent than native IGF-1.
Severe hypoglycaemia can cause sweating, shaking, confusion, behavioural change, loss of coordination, seizures, loss of consciousness, brain injury or death.
The authorised IGF-1 medicine mecasermin must be managed carefully around food intake because of its insulin-like hypoglycaemic effects.
There is no validated human LR3 protocol defining how product variability, nutrition, exercise, kidney function, liver function or other medicines alter this risk.
Absence of human case reports does not establish safety
An unauthorised substance lacks organised prescribing records and systematic pharmacovigilance. Serious reactions may be misattributed, unreported or never linked to the product.
Uncontrolled Tissue and Organ Growth Concerns
The receptor is distributed widely, making selective skeletal-muscle action biologically unlikely.
IGF-1 receptor activation can promote proliferation and survival in responsive tissues.
Animal studies involving LR3 have reported changes in organ weight, intestinal growth and cardiac-cell behaviour.
Potential concerns arising from excessive IGF signalling include enlargement of soft tissue, internal organs, tonsillar or lymphoid tissue and cardiac structures.
In growing individuals, IGF signalling can influence bones and growth plates. In adults, closed growth plates do not make all bone and connective-tissue effects impossible.
Clinical mecasermin information includes monitoring for scoliosis progression, slipped capital femoral epiphysis, tonsillar hypertrophy and cardiomegaly.
These are not proven LR3 outcomes, but no evidence shows that the modified analogue avoids them.
IGF-1 LR3, Cancer Biology and Neoplasia
The evidence does not show that LR3 causes cancer in humans, but its mechanism creates a serious unresolved concern.
IGF-1 receptor signalling promotes proliferation and resistance to programmed cell death in many experimental systems.
Numerous tumour cell lines express IGF-1 receptors and respond to IGF-1 or low-binding-protein-affinity analogues.
Reduced IGFBP affinity can weaken one extracellular mechanism that normally limits receptor access.
This does not mean that every exposure initiates cancer. Cancer development requires accumulated genetic and environmental changes.
A growth factor could nevertheless support survival or expansion of an existing abnormal cell population.
Mecasermin is contraindicated where active or suspected neoplasia is present. Post-marketing reports include benign and malignant neoplasms, with concern greater during unapproved use or exposure above recommended limits.
No adequate long-term human carcinogenicity or tumour-progression evidence exists for IGF-1 LR3.
“No proof that it causes cancer” is not proof of safety
The responsible conclusion is that human cancer risk remains unknown and biologically important, particularly where the substance is designed to reduce normal IGF-binding-protein control.
Other IGF-1 LR3 Safety Uncertainties
No reliable human adverse-effect profile exists for the standalone analogue.
Neurological and Intracranial Effects
Authorised recombinant IGF-1 treatment has been associated with headache and intracranial hypertension.
No evidence establishes whether LR3 creates a lower, similar or higher risk.
Fluid and Cardiovascular Effects
Changes in tissue growth, sodium handling and vascular signalling could influence swelling, blood pressure or cardiac function.
Long-term cardiovascular monitoring data for LR3 are absent.
Endocrine Feedback
Animal studies show that external IGF analogues can suppress growth hormone and alter endogenous IGF and binding-protein concentrations.
The recovery and clinical importance of these changes in humans are unknown.
Immune Reactions
Recombinant proteins can provoke immune responses, particularly where aggregates, incorrectly folded proteins or host-cell impurities are present.
No adequate human immunogenicity assessment was identified for research-market LR3.
Product-Quality Risks
- Incorrect active protein
- Native IGF-1 substituted for LR3
- R3 IGF-I substituted for Long R3 IGF-I
- Incorrect or missing N-terminal extension
- Failure to confirm the Glu3-to-Arg substitution
- Incorrect disulphide pairing
- Reduced cysteine residues
- Misfolded IGF-1 isomers
- Protein aggregates
- Oxidised methionine or other residues
- Truncated N-terminal products
- Host-cell proteins
- Residual bacterial DNA
- Bacterial endotoxin
- Residual purification reagents
- Incorrect net protein quantity
- Unverified sterile quality
- Degradation during transport
- Certificates unrelated to the supplied batch
How IGF-1 LR3 Research Material Should Be Analytically Tested
An 83-residue disulphide-rich protein requires substantially more analysis than a single HPLC purity result.
High-Resolution Mass Spectrometry
The observed intact mass should support the complete 83-residue LR3 protein and expected oxidation state.
Peptide Mapping and Tandem MS
Digestion and fragment analysis should confirm the extension, IGF-1 domain and Glu3-to-Arg substitution.
Disulphide-Bond Mapping
Testing should verify the three native IGF-1-domain disulphide linkages and exclude scrambled isomers.
Reduced-Thiol Assessment
Unexpected free thiols can indicate incomplete folding, reduction or instability.
Net Protein Assay
Active protein content should be quantified independently of water, buffer salts and total powder weight.
IGF-1 Receptor Potency
A validated cell-based assay should assess receptor phosphorylation or another relevant functional response.
Size-Exclusion Analysis
Orthogonal testing should assess dimers, oligomers and other higher-molecular-weight species.
Host-Cell and Endotoxin Testing
Recombinant bacterial material requires controls for host-cell proteins, residual DNA and endotoxin.
What a Meaningful IGF-1 LR3 Certificate Should Include
- Complete Long R3 IGF-I name
- Declared 83-residue length
- Full amino-acid sequence
- Confirmation of the 13-residue N-terminal extension
- Confirmation of the Glu3-to-Arg substitution
- Observed intact molecular mass
- Peptide-map sequence coverage
- Tandem-MS fragment evidence
- Disulphide-bond map
- Reduced-thiol result
- Misfolded-isomer assessment
- Net protein-content assay
- Chromatographic purity
- Aggregate result
- N-terminal truncation results
- Oxidation and deamidation profile
- IGF-1 receptor potency
- Declared expression system
- Host-cell-protein result
- Residual host-cell-DNA result
- Bacterial-endotoxin result
- Bioburden or sterility result where applicable
- Water-content result
- Batch-specific stability information
- Testing-laboratory identity
- Analytical methods and acceptance criteria
- A statement identifying tests not performed
Why “99% HPLC” Is Not Enough
Reverse-phase HPLC may show that one major species dominates under a particular separation method.
It does not prove the correct 83-residue sequence, R3 substitution, disulphide arrangement, receptor potency or absence of aggregates.
Incorrectly folded IGF-1 can have markedly lower receptor and binding-protein activity while remaining chemically similar.
HPLC purity also does not establish endotoxin control, sterile quality or suitability for human administration.
Folding is part of identity
For disulphide-rich growth factors, the correct three-dimensional structure is essential. Sequence and molecular mass alone cannot establish a biologically authentic product.
IGF-1 LR3 Regulation in the Peptides UK Market
Regulatory information checked on 22 July 2026.
No UK Marketing Authorisation Identified
No current UK marketing authorisation for a medicinal product containing Long R3 IGF-I or IGF-1 LR3 was identified in the official product sources reviewed.
It should not be presented as an approved treatment for muscle loss, sports recovery, injury repair, growth-hormone deficiency, IGF-1 deficiency, neuropathy, ageing or another condition.
Mecasermin authorisation does not extend to modified IGF-1 analogues.
How the MHRA Assesses Product Status
MHRA guidance states that a product may be medicinal where it is presented as preventing or treating disease.
A product may also be medicinal where it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.
Claims involving muscle growth, protein synthesis, glucose metabolism, healing, hormone replacement or tissue regeneration could contribute to medicinal-product classification.
The MHRA considers explicit and implied claims, pharmacological properties, intended purpose, labels, websites, social media, instructions, images, testimonials and customer reviews.
“Research Use Only” Wording
A research disclaimer does not automatically determine the legal classification of a product.
Where the surrounding material promotes personal administration or physiological effects, the complete presentation may be assessed.
Advertising Restrictions
Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product unless the required authorisation, registration or certificate is in force.
This section provides general regulatory education rather than legal advice.
IGF-1 LR3 and Competitive Sport
Long R3 IGF-I falls within an expressly prohibited growth-factor category.
The 2026 World Anti-Doping Agency Prohibited List includes insulin-like growth factor 1, mecasermin and IGF-1 analogues in section S2.
The prohibition applies at all times, both in and out of competition.
Long R3 IGF-I is an IGF-1 analogue and is therefore prohibited even where a supplier describes it only as a research protein.
Anti-doping laboratories have developed mass-spectrometry methods capable of detecting Long R3 IGF-I and selected degradation products.
Athletes are responsible for prohibited substances found in their samples under strict-liability principles.
IGF-1 LR3 is prohibited in sport
A claim that the molecule is undetectable, not specifically named or intended only for recovery does not alter its prohibited status.
Common IGF-1 LR3 Peptide Claims Examined
Most promotional claims turn receptor biology or animal findings into unsupported human promises.
“IGF-1 LR3 is a natural human hormone.”
It contains a human IGF-1 domain.
The extension and R3 substitution make it an engineered analogue not normally produced by the human body.
“Long means it has a very long half-life.”
“Long” refers to the 13 additional residues.
Poor IGFBP binding can increase clearance, and no validated human half-life was identified.
“It is ten times stronger than IGF-1.”
LR3 can be substantially more potent in systems containing inhibitory IGFBPs.
Potency differs between assays, cells and tissues and cannot be represented by one universal multiplier.
“It builds human muscle.”
IGF signalling affects muscle-cell biology in laboratory and animal models.
No adequate controlled human hypertrophy trial was identified.
“It grows only the muscle where it is used.”
No validated targeting evidence supports this statement.
Systemic distribution and effects on multiple local cell types are possible.
“It creates new muscle fibres.”
IGF signalling can influence developmental myogenesis in experimental systems.
No human evidence establishes meaningful new-fibre formation following LR3 exposure.
“It preserves all muscle during dieting.”
Some animal research investigated catabolic states.
One food-restriction study found improved body-weight retention without preservation of skeletal muscle.
“It repairs tendons and injuries.”
IGF-1 participates in repair-related biology.
No authorised or clinically proven LR3 treatment exists for tendon, ligament or muscle injury.
“It cannot cause low blood sugar.”
IGF signalling has insulin-like metabolic effects.
LR3 and related low-IGFBP-affinity variants produced potent hypoglycaemic effects in animals.
“It cannot affect internal organs.”
IGF-1 receptors are widely distributed.
Animal studies have reported organ-growth and intestinal-growth effects.
“There is no cancer concern.”
No evidence proves that LR3 causes human cancer.
Its proliferative and anti-apoptotic signalling creates an unresolved concern for existing abnormal cells.
“It is medically approved because IGF-1 is prescribed.”
Mecasermin is an authorised recombinant human IGF-1 medicine.
IGF-1 LR3 is a different molecule with no identified UK marketing authorisation.
“It is not banned because LR3 is not named.”
WADA prohibits IGF-1 and its analogues.
Long R3 IGF-I falls within that category.
“A 99% HPLC result proves it is genuine.”
HPLC provides one measure of chromatographic composition.
It does not establish full sequence, disulphide folding, receptor potency, aggregates or endotoxin control.
IGF-1 LR3 Compared With Related Growth Factors
Closely related names can hide major differences in pharmacology and regulatory status.
| Substance | Basic Identity | IGFBP Interaction | Important Distinction |
|---|---|---|---|
| Long R3 IGF-I | 83-residue extended E3R analogue | Very low affinity | Cell-culture growth factor with no authorised human use identified |
| Native IGF-1 | Natural 70-residue growth factor | High affinity | Physiologically regulated through binding proteins |
| Mecasermin | Recombinant human IGF-1 medicine | Native-like affinity | Authorised for severe primary IGF-1 deficiency |
| R3 IGF-I | 70-residue E3R analogue | Reduced affinity | No 13-residue extension |
| Long IGF-I | 83-residue extended analogue without E3R | Reduced but distinct profile | Not identical to Long R3 IGF-I |
| Des(1–3) IGF-I | 67-residue truncated analogue | Very low affinity | Missing the first three native residues |
| IGF-2 | Related endogenous growth factor | Binds several IGFBPs | Different receptor preferences and developmental role |
| Insulin | Pancreatic peptide hormone | Not regulated principally by IGFBPs | Primarily activates insulin receptors |
| Mechano growth factor | Term associated with an IGF-1 splice-variant-derived sequence | Different and incompletely defined | Not Long R3 IGF-I |
How to Assess IGF-1 LR3 and Peptides UK Evidence Critically
Use this checklist before accepting a scientific, safety or product-quality statement.
- Does the source call the molecule Long R3 IGF-I?
- Is it distinguished from native IGF-1?
- Is it distinguished from R3 IGF-I?
- Is the 83-residue length stated?
- Is the 13-residue extension identified?
- Is the Glu3-to-Arg substitution confirmed?
- Is the complete sequence provided?
- Was intact mass confirmed?
- Was peptide mapping performed?
- Were all three disulphide bonds mapped?
- Were misfolded isomers assessed?
- Were aggregates measured?
- Was receptor potency tested?
- Was net protein content measured?
- Was bacterial endotoxin tested?
- Were host-cell proteins assessed?
- Does the certificate match the supplied batch?
- Was the study conducted in cells, animals or humans?
- Did the cell system produce IGFBPs?
- Was the exposure a continuous animal infusion?
- Was muscle measured directly?
- Was strength measured?
- Were internal organs examined?
- Were glucose measurements reported?
- Was hypoglycaemia assessed?
- Was cancer or abnormal-cell growth considered?
- Was the finding independently replicated?
- Is mecasermin evidence being attributed to LR3?
- Is a cell-culture effect being described as human muscle growth?
- Is the source selling the product it describes?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profileIGF-1 LR3 Peptide UK Frequently Asked Questions
Evidence-led answers about Long R3 IGF-I structure, research, safety, sport and UK regulation.
What is IGF-1 LR3?
IGF-1 LR3 is an engineered 83-amino-acid analogue of human insulin-like growth factor 1.
What does LR3 mean?
“L” refers to the longer N-terminally extended sequence, while R3 refers to arginine replacing glutamic acid at position three of the IGF-1 domain.
How many amino acids does IGF-1 LR3 contain?
It contains 83 amino-acid residues: a 13-residue extension followed by a modified 70-residue IGF-1 domain.
Is IGF-1 LR3 naturally produced by the human body?
No. The human body produces native IGF-1, not the extended R3 analogue.
Is IGF-1 LR3 the same as IGF-1?
No. It contains an additional 13 residues and an amino-acid substitution that substantially reduce binding to IGF-binding proteins.
Is IGF-1 LR3 the same as mecasermin?
No. Mecasermin is recombinant human IGF-1. LR3 is a modified analogue with a different sequence and pharmacology.
Why was Long R3 IGF-I developed?
It was engineered primarily as a potent growth and survival supplement for mammalian cells used in biopharmaceutical production.
Why does LR3 bind poorly to IGF-binding proteins?
Its N-terminal extension and Glu3-to-Arg substitution alter regions involved in IGFBP interaction.
Does lower IGFBP binding make it stronger?
It can make LR3 more potent in systems where binding proteins would normally sequester native IGF-1. The effect is not identical in every cell or tissue.
Does “Long” mean it has a long half-life?
Not necessarily. “Long” refers to its additional sequence. Animal research suggests poor IGFBP binding can cause faster clearance despite potent biological effects.
What receptor does IGF-1 LR3 activate?
Its principal target is the type 1 IGF receptor. It may also influence insulin receptors and IGF-1/insulin hybrid receptors in some systems.
Does IGF-1 LR3 increase protein synthesis?
IGF-1-receptor signalling can activate protein-synthesis pathways in experimental cells and animals. No controlled human LR3 treatment effect has been established.
Does IGF-1 LR3 build muscle in humans?
No adequate controlled human trial was identified demonstrating safe increases in muscle size or strength.
Does it produce localised muscle growth?
No validated human evidence shows that LR3 remains confined to or selectively grows one chosen muscle.
Does IGF-1 LR3 help injuries heal?
IGF signalling participates in repair biology, but no authorised or clinically proven LR3 treatment exists for muscle, tendon, ligament or nerve injuries.
Does IGF-1 LR3 preserve muscle during dieting?
Human evidence is absent. One rat study found reduced body-weight loss during food restriction without preservation of skeletal muscle.
Can IGF-1 LR3 cause low blood sugar?
Potent glucose lowering has been reported in animal studies. The human risk is not quantified but is a major concern.
Can IGF-1 LR3 affect internal organs?
IGF-1 receptors occur in many tissues, and animal studies have reported organ and intestinal growth effects.
Does IGF-1 LR3 cause cancer?
No evidence establishes that it causes cancer in humans. Its proliferative and survival signalling creates an unresolved concern, particularly for existing abnormal cells.
Has IGF-1 LR3 been tested in humans?
No adequate published clinical programme for standalone LR3 administration was identified in the sources reviewed.
What is the human half-life of IGF-1 LR3?
No validated human pharmacokinetic half-life was identified.
Is IGF-1 LR3 approved in the UK?
No current UK marketing authorisation for Long R3 IGF-I was identified.
Does mecasermin approval make LR3 legal as a medicine?
No. Marketing authorisation applies to the exact authorised active substance, formulation, indication and manufacturer.
Does “Research Use Only” determine UK legal status?
No. The MHRA can consider intended use, pharmacological activity, claims, imagery, instructions and the complete commercial presentation.
Is IGF-1 LR3 prohibited by WADA?
Yes. IGF-1 and its analogues are prohibited at all times under the 2026 WADA Prohibited List.
Can anti-doping laboratories detect Long R3 IGF-I?
Published mass-spectrometry methods can detect Long R3 IGF-I and selected degradation products.
Why are disulphide bonds important?
They maintain the three-dimensional structure required for receptor activity. Incorrect cysteine pairing can produce a misfolded and biologically different protein.
Does 99% HPLC prove an LR3 product is authentic?
No. It does not prove full sequence, correct disulphide folding, receptor potency, aggregate control, endotoxin results or sterile quality.
What should an IGF-1 LR3 certificate include?
It should include the complete sequence, intact mass, R3 substitution, extension, peptide map, disulphide map, folding-isomer analysis, assay, aggregates, potency, host-cell impurities and endotoxin.
Does this article provide injection or bodybuilding instructions?
No. It does not provide preparation, reconstitution, injection, dosing, timing, cycling, site-specific administration or performance-enhancement guidance.
Key Takeaways
- IGF-1 LR3 is more commonly called Long R3 IGF-I in scientific literature.
- It is an engineered 83-residue analogue of human IGF-1.
- It contains a 13-residue N-terminal extension.
- Arginine replaces glutamic acid at position three of the IGF-1 domain.
- These modifications substantially reduce IGF-binding-protein affinity.
- Reduced IGFBP binding can increase receptor-accessible protein in experimental systems.
- Its principal established use is as a mammalian-cell-culture supplement.
- “Long” describes the extension rather than a proven prolonged human half-life.
- Animal studies demonstrate potent glucose-lowering effects.
- Animal studies also report broad organ and tissue-growth effects.
- No adequate human muscle-growth or performance trial was identified.
- No evidence establishes reliable site-specific muscle growth.
- No human injury-repair indication has been established.
- No reliable human pharmacokinetic or long-term safety profile exists.
- Hypoglycaemia is a major biologically plausible risk.
- Proliferative and anti-apoptotic signalling creates unresolved neoplasia concerns.
- IGF-1 LR3 is not the authorised medicine mecasermin.
- No UK marketing authorisation for LR3 was identified.
- IGF-1 analogues are prohibited at all times by WADA.
- Correct sequence, folding, potency, aggregate and endotoxin testing are essential.
Relevant It’s Me & You Clinic Peptides UK Resources
Explore related evidence-led articles and clinical contributor profiles.
HGH 191AA Peptide UK
Review the complete human growth-hormone protein and its relationship with endogenous IGF-1 production.
Browse related peptide guidesIGF-1 DES Peptide UK
Compare LR3 with a separate shortened IGF-1 analogue that also has reduced binding-protein affinity.
Browse related peptide guidesResearch Peptides UK
Browse the wider educational series on peptide identity, evidence, analytical testing and UK regulation.
Browse the Peptides UK education libraryDr Rimas Geiga
Learn more about the clinic’s evidence-led approach to metabolism, endocrinology and scientific health education.
View Dr Rimas Geiga’s profileReferences
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992;8(3):213–223. PubMed record
- Hunt L, Hacker DL, Grosjean F, et al. LONG R3 IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Molecular Biotechnology. 2007;34(2):201–208. PubMed record
- Flint DJ, Tonner E, Beattie J, Allan GJ. Several IGF-I analogues and IGF/IGFBP-3 complexes fail to mimic the effect of growth hormone upon lactation in the rat. Journal of Endocrinology. 1994. PubMed record
- Prelle K, Stojkovic M, Boxhammer K, et al. IGF-I and Long R3 IGF-I differently affect bovine embryo development and expression of IGF-binding proteins and IGF receptors. Endocrinology. 2001;142(3):1309–1316. PubMed record
- Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. Journal of Endocrinology. 1997;155(2):377–386. PubMed record
- Tomas FM, Knowles SE, Owens PC, et al. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins in rats. 1996. PubMed record
- Conlon MA, Tomas FM, Owens PC, et al. Long R3 IGF-I infusion stimulates organ growth but reduces circulating IGF-I, IGF-II and binding-protein concentrations in guinea pigs. Journal of Endocrinology. 1995;146(2):247–253. PubMed record
- Tomas FM, Knowles SE, Owens PC, et al. Anabolic effects of IGF-I and an IGF-I variant in normal female rats. Journal of Endocrinology. 1993. PubMed record
- Tomas FM, Knowles SE, Owens PC, Read LC, Ballard FJ. LR3 IGF-I ameliorates loss of body weight but not skeletal muscle during food restriction. 2001. PubMed record
- Milner SJ, Carver JA, Ballard FJ, Francis GL. Probing the disulphide-folding pathway of IGF-I and Long Arg3 IGF-I. Biotechnology and Bioengineering. 1999. PubMed record
- Yang Y, Wu J, Watson JT. Probing the folding pathways of Long R3 IGF-I and IGF-I through disulphide intermediates and mass spectrometry. Journal of Biological Chemistry. 1999;274(53):37598–37604. PubMed record
- Laajoki LG, Francis GL, Wallace JC, Carver JA, Keniry MA. Solution structure and backbone dynamics of Long Arg3 IGF-I. 2000. PubMed record
- Raschdorf F, Dahinden R, Maerki W, Richter W, Merryweather JP. Location of disulphide bonds in recombinant human insulin-like growth factors. Biomedical and Environmental Mass Spectrometry. 1988. PubMed record
- Mongongu C, Kuuranne T, Ericsson M, et al. Detection of Long R3 IGF-I, Des(1–3) IGF-I and R3 IGF-I using immunopurification and high-resolution mass spectrometry for anti-doping purposes. Drug Testing and Analysis. 2021. PubMed record
- World Anti-Doping Agency. 2026 Prohibited List. Section S2, peptide hormones, growth factors, related substances and mimetics. WADA 2026 Prohibited List
- European Medicines Agency. Increlex, mecasermin: European public assessment report. EMA Increlex page
- European Medicines Agency. Increlex product information and Summary of Product Characteristics. EMA product information
- Medicines and Healthcare products Regulatory Agency. MHRA Products database. Search UK authorised medicine information
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA borderline-product guidance
- Human Medicines Regulations 2012, Regulation 279. UK medicinal-product advertising restriction
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH analytical guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS laboratory guidance
